In the matched cohort of older patients with diabetes, presumed dementia onset occurred in 43 dulaglutide users and 69 SGLT2 inhibitor users over a median follow-up of 4.4 years.
In plain wordsIn matched records of older patients with diabetes, 43 dulaglutide users and 69 SGLT2 inhibitor users had presumed dementia onset events.
- Peptide
- Dulaglutide (Trulicity)
- Outcome
- Not applicablePresumed dementia onset events
- Study
n: not reported in source
- Comparator
- SGLT2 inhibitors
- Analysis
- Primary
- Outcome group
- Cognition and memory · Nervous system and cognition
- Studied dose
- Dose not stated · Median 4.4 yearsAs given in this study (human).
Measurements
- Dementia onset events
- 43 participants
- dulaglutide matched cohort
- Dementia onset events
- 69 participants
- SGLT2 inhibitor matched cohort
Source sentences
In the matched cohort, over a median follow-up of 4.4 years, the primary outcome event occurred in 69 participants in the SGLT2 inhibitor group and 43 in the dulaglutide group.
4 context sentences(design, population, supporting numbers)
The primary outcome was the presumed clinical onset of dementia.
Nationwide health care data of South Korea obtained from the National Health Insurance Service between 2010 and 2022.
Patients aged 60 years or older who have T2D and are initiating treatment with SGLT2 inhibitors or dulaglutide.
The 5-year risk ratios and risk differences comparing SGLT2 inhibitors with dulaglutide were estimated in a 1:2 propensity score-matched cohort adjusted for confounders.